Lung cancer recurrence after neoadjuvant immunotherapy
The Journal of Thoracic and Cardiovascular Surgery · 2025
DOI: 10.1016/j.jtcvs.2025.04.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Hao Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass; Department of Thoracic Surgery, Institution of Thoracic Oncology, Peking Un…. Hauptthemen laut MEDLINE: Lung Neoplasms, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To investigate recurrence risk and patterns following neoadjuvant immunotherapy (Neo-IO) for resectable lung cancer, with a focus on identifying optimal cutoffs of residual viable tumor percentage (%RVT) of the primary tumor as a prognostic indicator. METHODS: We conducted a retrospective analysis of patients with resectable non-small cell lung cancer who received Neo-IO with or without chemotherapy followed by lung resection, using data from our prospectively maintained clinical database. The %RVT of the primary tumor in the surgical specimen was quantified (0%-100%) according to pan-tumor immune-related pathologic response criteria. The optimal %RVT cutoffs, as a continuous covariate for recurrence-free survival (RFS), were determined using the Rhier function in the rolr R package. RESULTS: A total of 94 patients treated between October 2017 and April 2024 met the study's inclusion criterion, with a median follow-up of 16.3 months. Seventy-nine patients received Neo-IO combined with chemotherapy, and 15 patients received Neo-IO only. A pathologic complete response (pCR) was observed in 21 patients (22.3%), and a major pathologic response (MPR) was noted in 41 (43.6%). The median %RVT was 20.0% (range, 0%-100%). The estimated optimal %RVT cutoffs were 5% and 40%. Patients with ≥40% RVT demonstrated worse RFS compared to those with 5% to 40% RVT (P = .006) and those with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass; Department of Thoracic Surgery, Institution of Thoracic Oncology, Peking University People's Hospital, Beijing, China. Electronic address: hali11…
- Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Mass.
- Department of Thoracic Surgery, Institution of Thoracic Oncology, Peking University People's Hospital, Beijing, China.
- Division of Pathology, Brigham and Women's Hospital, Boston, Mass.
Zitieren
APA
Li, H., Pezeshkian, F., Xie, Y., Mazzola, E., Barcelos, R. R., Hooshmand, F., Han, T., Laaksonen, S., Sholl, L., Vega, C., Farhat, E. B., Bueno, R., Figueroa, P. U., & Swanson, S. (2025). Lung cancer recurrence after neoadjuvant immunotherapy. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2025.04.028
Vancouver
Li H, Pezeshkian F, Xie Y, Mazzola E, Barcelos RR, Hooshmand F, et al. Lung cancer recurrence after neoadjuvant immunotherapy. The Journal of Thoracic and Cardiovascular Surgery. 2025. doi:10.1016/j.jtcvs.2025.04.028
BibTeX
@article{Li2025,
author = {Li, Hao and Pezeshkian, Fatemehsadat and Xie, Yue and Mazzola, Emanuele and Barcelos, Rafael Ribeiro and Hooshmand, Fatemeh and Han, Tianxiao and Laaksonen, Sanna and Sholl, Lynette and Vega, Carla and Farhat, Elias Bou and Bueno, Raphael and Figueroa, Paula Ugalde and Swanson, Scott},
title = {Lung cancer recurrence after neoadjuvant immunotherapy},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2025},
doi = {10.1016/j.jtcvs.2025.04.028}
}
EUVIMED